| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
We have investigated causative roles of given genes or mutated genes in the development of malignant lymphoma and multiple myeloma using our high-throughput mouse model system, in which germinal center B cells (normal counterparts of many lymphomas) were induced in vitro, infected with retroviruses for gene of interest, and transplanted into mice. Results showed that a combination of CARD11 mutant and BCL6 or a combination of Myc and Bcl2 was sufficient for the development of lymphoma. Our models may provide a platform for the development of therapy of these lymphomas known as being associated with poor clinical outcome. Although we were unable to develop a mouse myeloma model within the assigned period of time, we have developed a Cre-LoxP-mediated gene expression system employing retrovirus vector, and thus will make an effort to accomplish the aims.
|
